Advertisement
Canada markets close in 5 hours 6 minutes

  • S&P/TSX

    21,995.37
    +123.41 (+0.56%)
     

  • S&P 500

    5,064.01
    +53.41 (+1.07%)
     

  • DOW

    38,478.81
    +238.83 (+0.62%)
     

  • CAD/USD

    0.7318
    +0.0017 (+0.23%)
     

  • CRUDE OIL

    82.21
    +0.31 (+0.38%)
     

  • Bitcoin CAD

    91,406.52
    +826.15 (+0.91%)
     

  • CMC Crypto 200

    1,442.01
    +27.25 (+1.92%)
     

  • GOLD FUTURES

    2,332.30
    -14.10 (-0.60%)
     

  • RUSSELL 2000

    2,001.92
    +34.45 (+1.75%)
     

  • 10-Yr Bond

    4.5860
    -0.0370 (-0.80%)
     

  • NASDAQ

    15,666.65
    +215.35 (+1.39%)
     

  • VOLATILITY

    16.29
    -0.65 (-3.84%)
     

  • FTSE

    8,039.07
    +15.20 (+0.19%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6837
    -0.0013 (-0.19%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

SIGA Technologies gets UK approval for monkeypox drug

Reuters
·1 min read

July 8 (Reuters) - SIGA Technologies Inc said on Friday the UK has approved its oral drug for treatment of monkeypox amid a surge in cases globally.

UK's approval for the drug tecovirimat, sold under the brand Tpoxx in the United States, is also for smallpox, cowpox, as well as complications caused by the smallpox vaccine, which uses a different virus from the same group called orthopoxviruses.

The oral drug is approved in the U.S. and Canada for only smallpox, but has approval in the European Union for all the three diseases and the vaccine complication.

The approval comes on the back of more than 7,600 cases of monkepox being reported in over 50 countries where the disease is not endemic, including more than 1,300 in the UK.

The WHO has reported three deaths, all of them in Africa. (Reporting by Leroy Leo in Bengaluru; Editing by Shounak Dasgupta)